2seventy bio
TSVT
TSVT was delisted on the 13th of May, 2025.
2 hedge funds and large institutions have $508K invested in 2seventy bio in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 137 closing their positions.
99% less funds holding
Funds holding: 139 → 2 (-137)
100% less capital invested
Capital invested by funds: $234M → $508K (-$234M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 137
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$23.1M |
| 2 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$21M |
| 3 |
BlackRock
New York
|
-$19.6M |
| 4 |
Morgan Stanley
New York
|
-$14.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13.9M |
TSVT Hedge Fund Activity: Q2 2025 in Review
2 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in 2seventy bio (TSVT) for Q2 2025, worth a combined $508K — down 100% from $234M a quarter earlier.
Sellers outnumbered buyers: 137 funds closed out of TSVT and 0 opened new positions — a net loss of 137 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Goldman Sachs, exiting entirely with an estimated $23.1M sold.
- 2 institutional investors held 2seventy bio (TSVT) as of Q2 2025, down from 139 in Q1 2025.
- Funds reported $508K of 2seventy bio stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new 2seventy bio positions in Q2 2025 and 137 closed out, a net change of -137 holders.
- The largest 2seventy bio seller in Q2 2025 was Goldman Sachs, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2025.